Spinal Generations v. DePuy Synthes: Five Orthopedic Patents Invalidated in Delaware
Spinal Generations, LLC brought an infringement action against DePuy Synthes, Inc. and affiliated Synthes entities over five U.S. patents covering spinal and proximal femoral fixation technology, including the TFNA nailing system. After 1,162 days of litigation, the Delaware District Court granted summary judgment of invalidity for lack of enablement on the adjudicated claims, delivering a full merits victory to DePuy Synthes.
Enablement defeats five orthopedic patents in Delaware district court
Spinal Generations, LLC filed suit on October 17, 2022 in the U.S. District Court for the District of Delaware against DePuy Synthes, Inc., Synthes (U.S.A.), LLC, and Synthes USA Products, LLC. The complaint alleged infringement of five U.S. patents — US8808337B2, US9949777B2, US8062270B2, US7527611B2, and US7575572B2 — covering orthopedic fixation technology including augmentation systems, helical blades, and the TFNA proximal femoral nailing system. The accused products included the TFNA system and TRAUMACEM V+ bone augmentation product.
The case concluded on December 22, 2025, when Judge Colm F. Connolly entered final judgment following the court’s earlier grant of DePuy Synthes’s motion for summary judgment of invalidity for lack of enablement (D.I. 219). The court invalidated claims 1–3, 8, and 14 of US8808337B2 and claims 1–9 and 11 of US7575572B2 — the adjudicated claims. Spinal Generations moved for reargument (D.I. 228), which the court denied, cementing the invalidity finding and leaving the defendant with a clean merits win.
At 1,162 days, the case ran well beyond median disposition times for Delaware patent dockets, suggesting contested claim construction and expert-intensive invalidity briefing. The enablement holding — rather than anticipation or obviousness — signals the court found the patents failed to teach a person skilled in the art how to make and use the full scope of the claimed inventions. What remains publicly unknown is whether the parties discussed settlement during the period between summary judgment and the reargument denial, and whether Spinal Generations will pursue an appeal to the Federal Circuit.
Filing to Judgment on the merits for Defendant in 1162 days
1,162 days — over 3 years from filing to final judgment, above median for Delaware patent cases
Summary judgment of invalidity: what the enablement ruling means for both parties
Lack of enablement: a foundational patent validity doctrine
Under 35 U.S.C. § 112, a patent must enable a person of ordinary skill in the art to make and use the full scope of the claimed invention. If the claims are broader than what the specification actually teaches, the patent is invalid for lack of enablement. Here, the court found that the adjudicated claims in US8808337B2 and US7575572B2 failed this standard — a high-bar outcome that voids the claims regardless of any infringement analysis.
§ 112 enablement invalidityAdjudicated claims permanently invalidated — no revenue stream from these patents
With final judgment entered and reargument denied, Spinal Generations no longer holds enforceable claims 1–3, 8, and 14 of US8808337B2 or claims 1–9 and 11 of US7575572B2 against DePuy Synthes or any other party. The invalidity finding has in rem effect, meaning these claims cannot be asserted against third parties either. Whether the remaining three asserted patents — US9949777B2, US8062270B2, and US7527611B2 — were fully adjudicated is not explicit in the public record.
Claims invalidated — in rem effectDePuy Synthes cleared to commercialise TFNA and related products
The summary judgment outcome provides DePuy Synthes with a strong litigation record: invalidity was established on the merits, not on procedural grounds. The TFNA proximal femoral nailing system and TRAUMACEM V+ augmentation products are no longer exposed to infringement liability under the adjudicated claims. This result is commercially significant given the scale of DePuy Synthes’s trauma product portfolio and the potential damages exposure over a multi-year infringement window.
Product freedom confirmed on the meritsEnablement bar raised for broad orthopedic fixation claims
This outcome reinforces that broad functional claims in orthopedic fixation patents — particularly those covering augmentation and nailing systems — face serious enablement scrutiny in Delaware. Competitors in the proximal femoral nailing and bone augmentation space may point to this ruling when challenging similarly broad claims. Patent holders in this sector should audit their existing portfolios for specification depth relative to claim scope before asserting or licensing.
Enablement risk for broad medtech claimsFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Spinal Generations, LLC | Company | Orthopedic IP licensing entity — holder of US8808337B2 and four related fixation patentsSearch in Eureka ↗ |
| Defendant | DePuy Synthes, Inc. | Company | DePuy Synthes, Inc. — global orthopedic device manufacturer, subsidiary of Johnson & JohnsonSearch in Eureka ↗ |
| Co-Defendant | Synthes (U.S.A.), LLC | Company | Search in Eureka ↗ |
| Co-Defendant | Synthes USA Products, LLC | Company | Search in Eureka ↗ |
| Plaintiff counsel | Jason Linger | Attorney | Counsel for Spinal Generations, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Lara Petersen | Attorney | Counsel for Spinal Generations, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Lawrence M. Hadley | Attorney | Counsel for Spinal Generations, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Richard Charles Weinblatt | Attorney | Counsel for Spinal Generations, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Stamatios Stamoulis | Attorney | Counsel for Spinal Generations, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Stephen E. Underwood | Attorney | Counsel for Spinal Generations, LLCSearch in Eureka ↗ |
| Plaintiff law firm | Stamoulis & Weinblatt LLC | Law Firm | Representing Spinal Generations, LLCSearch in Eureka ↗ |
| Defendant counsel | Abhishek Bapna | Attorney | Counsel for DePuy Synthes, Inc.Search in Eureka ↗ |
| Defendant counsel | Brian P. Egan | Attorney | Counsel for DePuy Synthes, Inc.Search in Eureka ↗ |
| Defendant counsel | Cameron Paul Clark | Attorney | Counsel for DePuy Synthes, Inc.Search in Eureka ↗ |
| Defendant counsel | Jack B. Blumenfeld | Attorney | Counsel for DePuy Synthes, Inc.Search in Eureka ↗ |
| Defendant counsel | Jeffrey S. Ginsberg | Attorney | Counsel for DePuy Synthes, Inc.Search in Eureka ↗ |
| Defendant law firm | Morris, Nichols, Arsht & Tunnell LLP | Law Firm | Representing DePuy Synthes, Inc.Search in Eureka ↗ |
| Presiding judge | Judge Colm F. Connolly | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The court’s order is unambiguous in scope: final judgment of invalidity is entered specifically on lack of enablement grounds against claims 1–3, 8, and 14 of US8808337B2 and claims 1–9 and 11 of US7575572B2. The language ‘finally adjudged invalid’ forecloses any further assertion of these claims in this jurisdiction. Notably, the order references only these two patents by adjudicated claims, leaving the disposition of the other three asserted patents — US9949777B2, US8062270B2, and US7527611B2 — not explicitly resolved on the face of the final judgment, which may warrant further review of the docket.
US8808337B2 — spinal and proximal femoral fixation systems
US8808337B2, filed under application number US12/427520, sits within a portfolio of five patents asserted by Spinal Generations covering orthopedic fixation technology. The patents collectively address augmentation systems, intramedullary nailing, helical blade constructs, and fixation screws — core mechanical components used in spinal stabilisation and proximal femoral fracture repair. The portfolio spans application filings from the mid-2000s through the early 2010s, reflecting a sustained development programme in load-bearing implant design.
The commercial significance of this portfolio lies in its overlap with DePuy Synthes’s TFNA and TFNA ADVANCED proximal femoral nailing systems — high-volume trauma products deployed globally. An assertion against these products carried potentially substantial damages exposure. The enablement-based invalidity outcome suggests the claims were drafted more broadly than the underlying specification could support, a pattern that courts and the USPTO have increasingly scrutinised in medtech. Competitors in the trauma fixation and bone augmentation space — including Stryker, Smith & Nephew, and Zimmer Biomet — should treat this outcome as a data point when evaluating the enforceability of similarly broad fixation patents.
Should you run an FTO against US8808337B2 and the Spinal Generations portfolio?
Any company developing or commercialising proximal femoral nailing systems, bone augmentation products, or helical blade fixation implants should note that claims 1–3, 8, and 14 of US8808337B2 and claims 1–9 and 11 of US7575572B2 have been judicially invalidated for lack of enablement. However, three further patents in the Spinal Generations portfolio — US9949777B2, US8062270B2, and US7527611B2 — were also asserted in this litigation, and their adjudicated status is not fully explicit in the public record. A targeted FTO remains warranted.
PatSnap Eureka’s FTO Search Agent can map your product’s technical features against the surviving claims across the full Spinal Generations portfolio, flag which claims remain enforceable post-judgment, and surface any continuation or divisional applications that could generate future exposure. For R&D teams designing next-generation nailing systems or augmentation products, Eureka’s claim-level analysis accelerates clearance decisions and reduces reliance on manual docket review.
Run a freedom-to-operate analysis on US8808337B2 to assess your product’s exposure
Run FTO in Eureka →Similar orthopedic fixation patent invalidity cases in Delaware District Court
Explore related § 112 enablement and invalidity disputes involving orthopedic implant and fixation patents litigated in the District of Delaware.
What this case signals for the orthopedic device IP landscape
A merits-based invalidity win for a major OEM signals rising enablement scrutiny for fixation patents in Delaware.
Enablement is a viable summary judgment vehicle in complex orthopedic cases
DePuy Synthes secured invalidity at summary judgment — not trial — on enablement grounds. This signals that Delaware courts are willing to resolve § 112 disputes early when the specification’s gap relative to claim scope is sufficiently clear. Patent owners in the orthopedic fixation space should assess whether their specifications can withstand this type of motion.
In rem invalidity creates third-party freedom-to-operate opportunities
The invalidated claims of US8808337B2 and US7575572B2 are now unenforceable against all parties, not just DePuy Synthes. Competitors marketing augmentation systems or proximal femoral nailing products who had previously monitored these patents — or taken licences as a precaution — should reassess their exposure and licensing costs in light of this outcome.
Spinal v DePuy — key questions answered
The court granted summary judgment of invalidity for lack of enablement under 35 U.S.C. § 112. The ruling invalidated claims 1–3, 8, and 14 of US8808337B2 and claims 1–9 and 11 of US7575572B2, finding the claims were not sufficiently enabled by their specifications. Plaintiff’s motion for reargument was subsequently denied.
Spinal Generations asserted five U.S. patents: US8808337B2, US9949777B2, US8062270B2, US7527611B2, and US7575572B2. The final judgment explicitly adjudicates claims in US8808337B2 and US7575572B2 for invalidity. The adjudicated status of the remaining three patents is not fully explicit in the public final judgment order.
The accused products included the TFNA Proximal Femoral Nailing System, TFNA Helical Blades, TFNA Screws, the TFNA ADVANCED system, Augmentation Systems, and TRAUMACEM V+ bone augmentation product — all within DePuy Synthes’s trauma and orthopedic fixation portfolio.
Yes. Patent invalidity judgments have in rem effect under U.S. law, meaning the adjudicated claims of US8808337B2 and US7575572B2 are unenforceable against any party, not merely DePuy Synthes. Competitors in the proximal femoral nailing and bone augmentation market who previously monitored these patents may now treat those specific claims as cleared.
With final judgment entered December 22, 2025, Spinal Generations has 30 days to file a notice of appeal to the Federal Circuit. An appeal is plausible given the size of the commercial stakes and the availability of a de novo review standard for enablement, which is a question of law. The public record does not confirm whether an appeal has been filed as of the judgment date.
PatSnap Eureka searches patents and litigation data to answer instantly.